Life Sciences & Healthcare Newsletters

Kempen European Life Sciences ECM update

Monthly update on Equity Capital Markets of European Life Sciences companies
Provides insights on market developments, financing transactions, share price developments and other relevant insights in the field of ECM
Example analysis from the March 2019 ECM update below

EU Life Sciences ABB* volume over the last five years

Over the last five years, the number of accelerated bookbuild offerings executed per year varied between 15-26 deals, with an average size between €44.7 - €80.5m
Three ABB transactions were executed in the first two months of 2019 (Biocartis, €55.5m; Oncopeptides, €53.3m; Nordic Nanovector, €22.9m), compared to one transaction in the same period in 2018
In 2015, over 50% of total ABB volume was raised in the first two months of the year, compared to 23% in 2016, 0% in 2017 and 3% in 2018

*Accelerated bookbuild offering
Source: Bloomberg, Kempen analysis as per 28 February 2019; included are Life Sciences deals on European regulated stock exchanges excluding United Kingdom (>€10m)

Kempen European Life Sciences M&A update

Bi-monthly update on Mergers & Acquisitions of European Life Sciences companies
Provides insights on the current M&A climate, recent developments, transactions and other relevant insights in the field of M&A
Example analysis from the March 2019 M&A update below

Europeans buy most European Life Sciences companies, but China and Japan are becoming increasingly active

On average, almost 2/3 of all Life Sciences M&A targets in Europe is acquired by European bidders and close to a quarter by North-American bidders
Interestingly, although numbers are still relatively small, the activity of Chinese and Japanese acquirers in European M&A has more than doubled since 2015, despite a drop in overall M&A volume

Footnote 1: Included are transactions involving a European target. Analysis is performed based on disclosed deal information. Minority stakes, and deal transactions below €25m are excluded.

Sources: Mergermarket, Bloomberg, Kempen Analysis

Subscribe now

Leave your company email address here to receive our Life Sciences & Healthcare Newsletters

Submitting your form

We have received your form

And we will get back to you soon.

Something went wrong

Please check your form for errors or try again later.

Life Sciences & Healthcare

Kempen Life Sciences & Healthcare is uniquely positioned as a dedicated specialist adviser. We combine our in-depth knowledge of the financial sector with a scientific background and extensive industry experience.

Mergers & Acquisitions

Kempen Corporate Finance offers a long track-record of successful mergers & acquisitions transactions throughout Europe. We offer independent advice to both listed and private companies and have extensive experience in both sell-side and buy-side transactions.

Equity Capital Markets

Kempen Equity Capital Markets offers independent advice and assistance in managing all processes required for the successful raising of funds via issuance of new shares as well as sell-downs of existing shares. We have extensive experience across Europe in a wide variety of transactions such as IPOs, follow-on capital increases, secondary offerings, share buy-backs and equity-linked transactions.